Item

Indonesia’s Daily Cases Surpass India, Marking New Epicenter

Title (Dublin Core)

Indonesia’s Daily Cases Surpass India, Marking New Epicenter

Description (Dublin Core)

Indonesia surpassed India’s daily Covid-19 case numbers, marking a new Asian virus epicenter as the spread of the highly-contagious delta variant drives up infections in Southeast Asia’s largest economy.
The country has seen its daily case count cross 40,000 for three straight days -- including a record high of 54,517 on Wednesday -- up from less than 10,000 a month ago. Officials are concerned that the more transmissible new variant is now spreading outside of the country’s main island, Java, and could exhaust hospital workers and supplies of oxygen and medication.
Indonesia’s current numbers are still far from India’s peak of 400,000 daily cases in May, and its total outbreak of 2.7 million is barely a tenth of the Asian giant’s 30.9 million. India, with a population roughly five times the size of Indonesia’s 270 million people, saw daily infections drop below 39,000 on Wednesday as its devastating outbreak wanes.
The Southeast Asian country reported about 900 deaths daily on average in the past seven days -- compared to just 181 a month ago -- while India reported an average of 1,027 daily fatalities.

Date (Dublin Core)

Creator (Dublin Core)

Contributor (Dublin Core)

Type (Dublin Core)

text story

Link (Bibliographic Ontology)

Controlled Vocabulary (Dublin Core)

Curator's Tags (Omeka Classic)

Contributor's Tags (a true folksonomy) (Friend of a Friend)

Collection (Dublin Core)

Date Submitted (Dublin Core)

07/14/2021

Date Modified (Dublin Core)

07/31/2021

Date Created (Dublin Core)

07/13/2021

Item sets

This item was submitted on July 14, 2021 by Angelica Ramos using the form “Share Your Story” on the site “A Journal of the Plague Year”: http://mail.covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA